Zhou, Xi
Weng, Yue
Jiang, Tiantian
Ou, Wenxin
Zhang, Nan
Dong, Qian
Tang, Xiaoqiong
Funding for this research was provided by:
The mechanism of doxorubicin promoting atherosclerosis in lymphoma patients through NF-κB/miR-33 signaling pathway (No. cstc2019jcyj-msxmX0043)
Study on early cardiotoxicity of antitumor drugs in lymphoma patients (No. 2021MSXM276)
Article History
Received: 13 November 2022
Accepted: 12 June 2023
First Online: 13 October 2023
Declarations
:
: The authors declare that there are no competing interests.
: The study was registered in Chinese Clinical Trial and the date of first registration was 25/12/2021 under registration number ChiCTR2100054721. This study was conducted in accordance with the Declaration of Helsinki and approved by the ethics committee of the First Affiliated Hospital of Chongqing Medical University (Approval NO. 2018–016). Informed consent was obtained from all participated patients before the commencement of the interview and ultrasound examination.
: Not applicable.